Clinical Trial Update: Effect of Capivasertib on ctDNA in ER Positive Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating capivasertib on circulating tumor DNA in estrogen receptor-positive breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• Capivasertib (capivasertib)

Snippet

Sponsor: Imperial College London | Conditions: Breast Cancer, Oestrogen Receptor Positive Breast Cancer | Phase 2 | Status: WITHDRAWN